secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cidara Therapeutics, Inc. (—)
CIK:        0001610618
Form:       8-K
Filed at:   2025-06-20T23:59:59+00:00
Accession:  0001610618-25-000072
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cidara shareholders OK doubling authorized shares to 100M and adding 2.88M shares to equity plan
--------------------------------------------------------------------------------

- Shareholders approved certificate amendment to increase authorized common shares from 50M to 100M, effective June 18, 2025.
- 2024 Equity Incentive Plan amended to increase share reserve by 2,880,000 shares; approved by stockholders.
- Elected Jeffrey Stein, Bonnie Bassler, and Ryan Spencer as Class I directors for terms expiring at 2028 annual meeting.
- Ratified Ernst & Young as independent auditor for FY2025; advisory say-on-pay passed.
- Voting results: Charter amendment 13,042,275 for, 97,601 against; Equity plan 7,791,328 for, 3,033,052 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610618/000161061825000072/0001610618-25-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610618/000161061825000072/cdtx-20250618.htm
  HTML page:      https://secwatch.observer/filing/0001610618-25-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer